Concepts (94)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Education, Pharmacy | 3 | 2019 | 102 | 1.720 |
Why?
|
| Students, Pharmacy | 2 | 2021 | 79 | 1.290 |
Why?
|
| Drug Information Services | 3 | 2020 | 10 | 0.980 |
Why?
|
| Librarians | 1 | 2021 | 9 | 0.790 |
Why?
|
| Video Games | 1 | 2019 | 39 | 0.660 |
Why?
|
| Computer-Assisted Instruction | 1 | 2019 | 74 | 0.660 |
Why?
|
| Problem-Based Learning | 1 | 2019 | 72 | 0.650 |
Why?
|
| Curriculum | 2 | 2019 | 575 | 0.630 |
Why?
|
| Education, Distance | 1 | 2018 | 34 | 0.630 |
Why?
|
| Academic Medical Centers | 3 | 2019 | 281 | 0.610 |
Why?
|
| Faculty, Pharmacy | 1 | 2017 | 13 | 0.600 |
Why?
|
| Mobile Applications | 1 | 2019 | 138 | 0.590 |
Why?
|
| Pharmaceutical Preparations | 1 | 2017 | 101 | 0.560 |
Why?
|
| Periodicals as Topic | 1 | 2018 | 158 | 0.530 |
Why?
|
| Teaching | 1 | 2017 | 169 | 0.530 |
Why?
|
| Learning | 1 | 2017 | 186 | 0.520 |
Why?
|
| Urinalysis | 1 | 2014 | 27 | 0.460 |
Why?
|
| Hospitals, Psychiatric | 1 | 2014 | 59 | 0.450 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2014 | 52 | 0.450 |
Why?
|
| Unnecessary Procedures | 1 | 2014 | 49 | 0.450 |
Why?
|
| Urinary Tract Infections | 1 | 2014 | 71 | 0.440 |
Why?
|
| Quinolones | 1 | 2012 | 60 | 0.400 |
Why?
|
| Piperazines | 1 | 2012 | 206 | 0.370 |
Why?
|
| Schizophrenia | 1 | 2012 | 206 | 0.370 |
Why?
|
| Triazoles | 1 | 2010 | 43 | 0.350 |
Why?
|
| Antipsychotic Agents | 1 | 2012 | 247 | 0.350 |
Why?
|
| Documentation | 1 | 2009 | 83 | 0.320 |
Why?
|
| Information Storage and Retrieval | 1 | 2009 | 49 | 0.320 |
Why?
|
| Anticonvulsants | 1 | 2010 | 223 | 0.310 |
Why?
|
| Seizures | 1 | 2010 | 279 | 0.300 |
Why?
|
| Software | 1 | 2009 | 418 | 0.270 |
Why?
|
| Epilepsy | 1 | 2010 | 336 | 0.260 |
Why?
|
| Chemistry, Pharmaceutical | 2 | 2014 | 35 | 0.200 |
Why?
|
| Information Literacy | 1 | 2021 | 2 | 0.200 |
Why?
|
| Writing | 1 | 2021 | 29 | 0.190 |
Why?
|
| Humans | 11 | 2021 | 68618 | 0.180 |
Why?
|
| Information Dissemination | 2 | 2014 | 113 | 0.180 |
Why?
|
| South Carolina | 2 | 2019 | 2752 | 0.180 |
Why?
|
| Preceptorship | 1 | 2020 | 35 | 0.170 |
Why?
|
| Michigan | 1 | 2019 | 68 | 0.170 |
Why?
|
| Educational Measurement | 2 | 2020 | 254 | 0.170 |
Why?
|
| Professional-Patient Relations | 1 | 2020 | 71 | 0.170 |
Why?
|
| Telephone | 1 | 2020 | 160 | 0.160 |
Why?
|
| Decision Making, Organizational | 1 | 2019 | 23 | 0.160 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2019 | 47 | 0.160 |
Why?
|
| Cost Savings | 1 | 2019 | 110 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 2 | 2016 | 1026 | 0.160 |
Why?
|
| Multimedia | 1 | 2017 | 15 | 0.150 |
Why?
|
| Program Development | 1 | 2018 | 240 | 0.150 |
Why?
|
| Attitude | 1 | 2017 | 121 | 0.140 |
Why?
|
| Linezolid | 1 | 2016 | 7 | 0.140 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2016 | 7 | 0.140 |
Why?
|
| Vancomycin | 1 | 2016 | 60 | 0.130 |
Why?
|
| Communication | 2 | 2020 | 329 | 0.130 |
Why?
|
| Young Adult | 2 | 2019 | 5717 | 0.130 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2016 | 92 | 0.130 |
Why?
|
| Colony-Forming Units Assay | 1 | 2014 | 78 | 0.120 |
Why?
|
| Utilization Review | 1 | 2014 | 48 | 0.110 |
Why?
|
| Bacteriological Techniques | 1 | 2014 | 49 | 0.110 |
Why?
|
| Drug Therapy | 1 | 2014 | 71 | 0.110 |
Why?
|
| Pharmacists | 1 | 2014 | 125 | 0.110 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 567 | 0.100 |
Why?
|
| Drug Prescriptions | 1 | 2014 | 135 | 0.100 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 235 | 0.100 |
Why?
|
| Aripiprazole | 1 | 2012 | 43 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2014 | 383 | 0.100 |
Why?
|
| Adult | 3 | 2019 | 21403 | 0.090 |
Why?
|
| Epilepsies, Partial | 1 | 2010 | 24 | 0.090 |
Why?
|
| Off-Label Use | 1 | 2010 | 17 | 0.090 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2010 | 84 | 0.090 |
Why?
|
| Syndrome | 1 | 2010 | 255 | 0.090 |
Why?
|
| Poison Control Centers | 1 | 2009 | 6 | 0.080 |
Why?
|
| Comorbidity | 1 | 2014 | 1426 | 0.080 |
Why?
|
| Drug Resistance | 1 | 2010 | 223 | 0.080 |
Why?
|
| Aged | 3 | 2016 | 14862 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 4848 | 0.080 |
Why?
|
| Counseling | 1 | 2010 | 280 | 0.080 |
Why?
|
| Data Collection | 1 | 2009 | 420 | 0.070 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 2279 | 0.070 |
Why?
|
| Male | 3 | 2019 | 37321 | 0.070 |
Why?
|
| Female | 3 | 2019 | 38074 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2009 | 622 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 931 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2016 | 7277 | 0.060 |
Why?
|
| Adolescent | 2 | 2016 | 8912 | 0.060 |
Why?
|
| Middle Aged | 2 | 2016 | 21147 | 0.040 |
Why?
|
| Reimbursement Mechanisms | 1 | 2019 | 37 | 0.040 |
Why?
|
| Child | 1 | 2010 | 6405 | 0.040 |
Why?
|
| Drug Costs | 1 | 2019 | 87 | 0.040 |
Why?
|
| United States | 1 | 2009 | 7367 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2016 | 346 | 0.030 |
Why?
|
| Length of Stay | 1 | 2016 | 780 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 2800 | 0.020 |
Why?
|
| Hospitalization | 1 | 2016 | 978 | 0.020 |
Why?
|